APLM
Apollomics Inc. Class A Ordinary Shares
$6.920+-0.000 (-0.000%)
Real-time Price
Price Chart
Loading Chart...
Key Metrics
Market Metrics
Open
$6.920
High
$6.920
Low
$6.920
Volume
0.00M
Company Fundamentals
Trading Stats
Related News
GlobeNewswire
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for
View more
GlobeNewswire
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung
View more
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.